Featured Press Releases

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

With New Offerings Like MIC+B12 Injections, Metformin Combinations, and More, Shed Expands Its Weight Management Support

With New Offerings Like MIC+B12 Injections, Metformin Combinations, and More, Shed Expands Its Weight Management Support

  • 25 Jun 2025

Shed, a modern wellness company focused on helping individuals feel and function their best,...

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

SeoulTech researchers unveil a novel approach to understanding PFOS-induced neurotoxicity, advancing environmental health studies

SeoulTech researchers unveil a novel approach to understanding PFOS-induced neurotoxicity, advancing environmental health studies

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

ProductLife Group Appoints Dr. James Burt as CEO

ProductLife Group Appoints Dr. James Burt as CEO

  • ProductLife Group
  • 24 Mar 2026
Constance Sabbagh Appointed as General Manager as Avanzanite Expands French Operations

Constance Sabbagh Appointed as General Manager as Avanzanite Expands French Operations

  • Avanzanite Bioscience B.V.
  • 24 Mar 2026
Emerging From Stealth, Oryon Cell Therapies Targets Autologous Neuron Replacement for Parkinson’s Disease and Neurodegenerative Disorders

Emerging From Stealth, Oryon Cell Therapies Targets Autologous Neuron Replacement for Parkinson’s Disease and Neurodegenerative Disorders

  • Oryon Cell Therapies
  • 23 Mar 2026
Samsung Biologics Labor Union Warns of

Samsung Biologics Labor Union Warns of "Structural Supply Chain Risk" Amid Labor Dispute, Citing Systemic Governance Failures

  • Samsung Biologics Labor Union
  • 23 Mar 2026
Convergent Therapeutics Appoints Michael Rossi to Board

Convergent Therapeutics Appoints Michael Rossi to Board

  • Convergent Therapeutics Inc.
  • 20 Mar 2026
Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

  • Johnson & Johnson
  • 06 Mar 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.